Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- The Phase 1 trial of CRB-701 in China is ahead of schedule.
- Preliminary clinical data shows CRB-701 has a longer half-life and reduced levels of circulating free MMAE compared to PADCEV®.
- The IND submission for CRB-601 is on track for Q4 2023.
- None.
- CRB-701 Phase 1 trial in
China is ahead of schedule with dose escalation completion expected Q4 2023 andU.S. clinical trial start planned for Q1 2024 - Preliminary clinical PK data indicates CRB-701 has a longer half-life and reduced levels of circulating free MMAE relative to published data for PADCEV®
- CRB-601 IND submission is on track for Q4 2023
"During the second quarter, substantial progress was made advancing CRB-701, our next generation Nectin-4 antibody drug conjugate (ADC), in-licensed earlier this year from CSPC Pharmaceutical Group (CSPC)" said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Following a recent visit to CSPC in
"Development of our anti-aVb8 mAb CRB-601, is also ongoing and we were pleased to present the latest pre-clinical data for this asset at the AACR 2023 annual meeting in April," continued Dr. Cohen. "The data that was presented builds upon the robust target engagement previously presented alone and in combination with anti-PD-1. We believe this data reinforces the potential of this new approach in blocking activation of TGFβ locally in the TME. We plan to submit our Investigational New Drug (IND) application for CRB-601 in Q4 2023 and anticipate initiating our Phase 1 clinical trial in the first half of 2024. We note that key competitive programs from Pfizer and AbbVie have progressed to Phase 2 clinical trials, and we see this as supportive evidence that this class of drugs warrant further clinical exploration. It will be a busy 12 months for us, as we continue our evolution into a precision oncology company, and advance both of our programs into the clinic in the US."
Key Corporate and Program Updates:
- CRB-701 next generation Nectin-4 ADC:
- The dose exploration of CRB-701 in Nectin-4 positive solid tumors is ahead of schedule. CSPC, our development partner, is enrolling its Phase 1 dose escalation study in
China and Corbus now estimates this escalation will be completed by the end of 2023 and plans to initiate an abbreviated Phase 1 in the US in the first quarter of 2024 leveraging the clinical experience fromChina . - Preliminary clinical pharmacology data indicates CRB-701 is differentiated from PADCEV® with an increased half-life and reduced levels of circulating free monomethyl auristatin E (MMAE).
- Corbus licensed CRB-701 from CSPC in February 2023 and has exclusive development and commercialization rights in
the United States ,Canada , the European Union (including the European Free Trade Area), theUnited Kingdom , andAustralia . - Nectin-4 is a clinically validated tumor associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV® (SeaGen/Astellas) is approved for use in late metastatic urothelial cancer and recently received an expanded label from the Food and Drug Administration based on accelerated approval for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
- CRB-701 is designed to achieve an improved therapeutic index and will be explored in urothelial cancer, as well as a range of other Nectin-4 expressing solid tumors.
- CRB-701 has key features that support a differentiated profile including a novel Nectin-4 antibody and a site-specific conjugation linker that results in faster ADC internalization, longer half-life, and reduced payload release in plasma. Pre-clinical and dose escalation data demonstrates the potential to achieve higher exposures with CRB-701 resulting in an opportunity to improve the therapeutic index.
- CRB-601 blocking the activation of TGFβ
- CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody (mAb) designed to block the activation of latent TGFβ within the tumor micro-environment (TME). CRB-601 significantly inhibits tumor growth as a monotherapy in murine models and enhances the efficacy of anti-PD-1 immunotherapy as a combination in checkpoint inhibitor (CPI) sensitive and CPI-resistant tumor models.
- Corbus presented pre-clinical data at the American Association of Cancer Research (AACR) 2023 annual meeting indicating that CRB-601 exhibited dose dependent tumor growth inhibition (TGI) in the EMT6 tumor model which was significantly augmented in combination with anti-PD-1 therapy. These effects were associated with changes in TME immune cell populations with marked increases in infiltrating T cells, NK cells and M1 polarized macrophages. Efficacy correlated with cell surface αvβ8 occupancy by CRB-601. CRB-601 treatment downregulated phosphorylation of SMAD proteins, pSMAD2 and pSMAD3, consistent with blockade of the TGFβ signaling pathway.
- The IND submission for CRB-601 is anticipated in Q4 2023, and the Company expects to enroll the first patient in its Phase 1 study in the first half of 2024.
- We note that recent events from other development programs of mAb with a similar mechanism of action including those of Pfizer and AbbVie indicate their advancement into Phase 2 clinical trials.
Financial Results for Quarter Ended June 30, 2023:
The Company reported a net loss of approximately
Operating expenses decreased by
As of June 30, 2023, the company has
About Corbus
Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
---tables to follow---
Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Balance Sheets (Unaudited) | ||||||||
June 30, 2023 | December 31, 2022 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 8,349,346 | $ | 17,002,715 | ||||
Investments | 28,216,560 | 42,194,296 | ||||||
Restricted cash | 192,475 | 192,475 | ||||||
Prepaid expenses and other current assets | 1,515,616 | 791,616 | ||||||
Total current assets | 38,273,997 | 60,181,102 | ||||||
Restricted cash | 477,425 | 477,425 | ||||||
Property and equipment, net | 1,273,602 | 1,613,815 | ||||||
Operating lease right of use assets | 3,486,416 | 3,884,252 | ||||||
Other assets | 211,943 | 155,346 | ||||||
Total assets | $ | 43,723,383 | $ | 66,311,940 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Notes payable | $ | 51,157 | $ | 353,323 | ||||
Accounts payable | 1,505,734 | 2,173,963 | ||||||
Accrued expenses | 6,418,803 | 5,999,252 | ||||||
Derivative liability | 36,868 | 36,868 | ||||||
Operating lease liabilities, current | 1,357,240 | 1,280,863 | ||||||
Current portion of long-term debt | 7,016,096 | 2,795,669 | ||||||
Total current liabilities | 16,385,898 | 12,639,938 | ||||||
Long-term debt, net of debt discount | 11,319,365 | 15,984,426 | ||||||
License agreement payable, noncurrent | 2,500,000 | — | ||||||
Other long-term liabilities | 22,205 | 22,205 | ||||||
Operating lease liabilities, noncurrent | 3,975,329 | 4,675,354 | ||||||
Total liabilities | 34,202,797 | 33,321,923 | ||||||
Stockholders' equity | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 442 | 417 | ||||||
Additional paid-in capital | 428,153,252 | 425,196,359 | ||||||
Accumulated deficit | (418,609,320) | (392,080,667) | ||||||
Accumulated other comprehensive loss | (23,788) | (126,092) | ||||||
Total stockholders' equity | 9,520,586 | 32,990,017 | ||||||
Total liabilities and stockholders' equity | $ | 43,723,383 | $ | 66,311,940 | ||||
Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||||||
For the Three Months | For the Six Months | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 4,248,705 | $ | 2,499,642 | $ | 17,637,048 | $ | 5,785,878 | ||||||||
General and administrative | 3,940,286 | 4,840,368 | 7,848,968 | 10,071,291 | ||||||||||||
Litigation Settlement | — | 5,000,000 | — | 5,000,000 | ||||||||||||
Total operating expenses | 8,188,991 | 12,340,010 | 25,486,016 | 20,857,169 | ||||||||||||
Operating loss | (8,188,991) | (12,340,010) | (25,486,016) | (20,857,169) | ||||||||||||
Other expense, net: | ||||||||||||||||
Other income (expense), net | 182,657 | (208,683) | 412,164 | (402,034) | ||||||||||||
Interest expense, net | (775,586) | (490,339) | (1,453,608) | (949,248) | ||||||||||||
Foreign currency exchange loss, net | (1,921) | (209,856) | (1,193) | (477,679) | ||||||||||||
Other expense, net | (594,850) | (908,878) | (1,042,637) | (1,828,961) | ||||||||||||
Net loss | $ | (8,783,841) | $ | (13,248,888) | $ | (26,528,653) | $ | (22,686,130) | ||||||||
Net loss per share, basic and diluted | $ | (2.05) | $ | (3.18) | $ | (6.27) | $ | (5.44) | ||||||||
Weighted average number of common shares outstanding, basic and diluted | 4,277,701 | 4,170,464 | 4,229,894 | 4,170,255 | ||||||||||||
Comprehensive loss: | ||||||||||||||||
Net loss | $ | (8,783,841) | $ | (13,248,888) | $ | (26,528,653) | $ | (22,686,130) | ||||||||
Other comprehensive income (loss): | ||||||||||||||||
Change in unrealized gain (loss) on marketable debt securities | 44,681 | 50,373 | 102,304 | (56,875) | ||||||||||||
Total other comprehensive income (loss) | 44,681 | 50,373 | 102,304 | (56,875) | ||||||||||||
Total comprehensive loss | $ | (8,739,160) | $ | (13,198,515) | $ | (26,426,349) | $ | (22,743,005) | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-reports-second-quarter-2023-financial-results-and-provides-corporate-update-301895599.html
SOURCE Corbus Pharmaceuticals
FAQ
What is the status of the CRB-701 Phase 1 trial in China?
How does CRB-701 compare to PADCEV®?
When is the IND submission for CRB-601 expected?
